SKIN RNS 13th July ;
"Once initial testing on the Affimers is completed over the next few weeks,"
2/8 "validation of the sensors on the real SARS-CoV-2 virus will be carried out at the containment level 3 ("CL3") laboratory in the University of Aberdeen."
"Upon successful completion of the evaluation, Integumen and the Avacta will enter into a supply agreement"
3/8 Furthermore ;
"Microtox BT has undergone extensive internal testing"
"Microtox PD has now successfully completed initial spike protein testing and validation"
and detects "the spike protein of SARS-CoV-2 in real-time for those with a high viral load."
4/8 SKIN RNS 24th Sept ;
"Further to the announcement of 13 July 2020. . . the evaluation of under the MTA has been successful and consequently a Memorandum of Understanding has been signed with Avacta for a commercial agreement, subject to contract."
5/8 So (internal) studies and validation to date, just like with AVCTs other Covid related programmes, have demonstrated enough to make a commercial agreement worthwhile.
So again we have further demonstration that Affimers can be effective, in yet another form of diagnostics.
6/8 There is still much to learn about this particular deal but what I really like about all this, is that Affimers led diagnostics, keep proving themselves to be commercially effective.
The AVCT Covid story remains a big one but I really am more excited by, is what the
7/8 combination of this progress (studies, relationships, experience, partnerships, department growth, ISO accreditation, revenues), will now go on to deliver for the AVCT platform in the future.
AVCTs own moonshot, are of course the Cancer therapies but time and again, I keep
8/8 saying it, that the diagnostic pipeline, driven by Covid, can and I think will, really deliver for AVCT and their shareholders.
All of which offers a fantastic opportunity to truly explore said therapy opportunities, whilst giving shareholders a really solid invest platform.
1/16
It's difficult to call this market but my view is that assuming no more operational glitches #TGR now steadily re-rates as the operations sign off the various stages to 30ktpa.
2/ Front-end valuations should depend on where graphite prices go but as Syrah demonstrated yesterday (graphite fines not large flake) orders are buoyant.
Forward orders there running at 90,000 tons which are 50% of their current yearly output. So substantial.
3/ Note also Syrah cannot produce for less than FOB C1 $543/t even at 15,000 tons per month output and that's fines.
It is clear after last night's presentation that TGR C1 costs have also risen but this is to be expected in this current market.
1/12
Here are Verde Agritech's expected sales targets for 2022 which were revised in May and offer a significant read across to #HMI and what it can achieve this year and also.
1/9 In a previous #HMI thread, I highlighted that the $600k write-down in the FY2021 accounts meant that trade debtors (so effectively trade receivables) almost doubled between YE 2020 and YE 2021.
1/18
I've been running an extensive exercise on Verde Agritech also a relatively new but expanding fertiliser producer based just c. 70km from #HMI in Minas Gervais in Brazil. The results to date are rather fascinating and certainly worthy of review.
2/ Verde is a TSX-listed producer with a current plant capacity nearly double the size of HMI (0.6Mtpy) but with a phase 2 expansion due to come online in 2023 which would take output to 2.4Mtpy.
So a much bigger operation to come and soon.
3/ Those that remember my 5th July numbers on #HMI sales prices will perhaps remember that they demonstrated a $53.20/t average sale price for 2021.
At the average achieved AUD/BRL for 2021 of 4.054, this equated to an average price of BRL216.
1/7 Based on what I have just talked about if #HMI had received all the monies from its sales in 2021 then this would have amounted to $4.52m and the business would have been profitable at the operating level in 2021.
2/ What's more, the $4.454m paid out in 2021 reflects more accurately the true costs to run the business over the course of one year.
One cannot conclude exactly how much HMI produced in 2021 because the cash receipts reflect payment dates and not when the goods were received.
3/ Inventory was fairly minimal which reflects an operation that leans towards producing to order.
However, the costs associated with administration clearly eat up the vast majority of this with the consolidated statement accounting for c. $3.85m in the period.